Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. MYMD
MYMD logo

MYMD Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
4.34M
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
-6.86M
EV/OCF(TTM)
--
P/S(TTM)
--
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).
Show More

Events Timeline

No data

No data

News

Newsfilter
6.8
2024-07-24Newsfilter
TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol "TNFA" Effective Before Market Open Today
  • Company Name and Stock Symbol Change: TNF Pharmaceuticals, Inc. (formerly MyMD Pharmaceuticals, Inc.) has changed its stock symbol to "TNFA" on the Nasdaq Capital Market, reflecting its focus on developing therapies that inhibit TNF-alpha to regulate the immune system.

  • Therapeutic Focus: The company is advancing its lead clinical candidate, MYMD-1®, which aims to block excess TNF-alpha activity to treat age-related diseases and inflammatory conditions, alongside another drug platform targeting chronic pain and epilepsy.

businesswire
6.8
2024-07-22businesswire
MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.
  • Company Rebranding: TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, has announced its rebranding and will begin trading under the new stock symbol "TNFA" on July 24, 2024, reflecting its focus on developing therapies targeting TNF-alpha related diseases.

  • Clinical Development of MYMD-1: The company is advancing mid-stage clinical trials for its lead drug candidate, MYMD-1, an oral TNF-alpha inhibitor aimed at treating sarcopenia and other autoimmune and inflammatory conditions, following positive results from a Phase 2 study.

SeekingAlpha
6.8
2024-07-22SeekingAlpha
MyMD Pharma announces rebranding to TNF Pharmaceuticals
  • Company Rebranding: TNF Pharmaceuticals, previously known as MyMD Pharmaceuticals, has officially rebranded and will begin trading under the new symbol "TNFA" on July 24, 2024.

  • Clinical Trials Announcement: The company plans to initiate mid-stage clinical trials for its TNF-alpha inhibitor drug MYMD-1 following positive results from Phase 2 studies.

Benzinga
6.4
2024-06-26Benzinga
Latest Key Hires & Board Changes In Cannabis Industry: Canopy Growth, Acreage And More
  • Leadership Changes in Cannabis Industry:

    • Margaret Brodie nominated as EY Entrepreneur Of The Year 2024 finalist for Rubicon Organics Inc.
    • Canopy Growth Corporation appoints Ryan Keith as head of clinics.
    • Acreage Holdings names Rebecca Kirk as chief operating officer effective July 1, 2024.
    • Charlotte’s Web Holdings appoints Erika Lind as CFO, replacing Jessica Saxton.
    • MyMD Pharmaceuticals appoints Mitchell Glass, M.D., as president and chief medical officer.
  • Board of Directors Elections and Resignations:

    • TerrAscend Corp. elects new directors including Craig Collard and Kara DioGuardi.
    • Nova Cannabis Inc. elects Zachary George and Marcie Kiziak to the board.
    • Wendy Berger steps down from Green Thumb Industries' board after nearly a decade of service.
  • Insights from Wendy Berger:

    • Berger focuses on future participation in the cannabis industry and her business, WBS Equities, LLC.
    • She emphasizes looking ahead and not dwelling on the past, sharing valuable insights at Benzinga events.
SeekingAlpha
6.4
2024-06-21SeekingAlpha
MyMD Pharmaceuticals files to sell 473,841 shares of common stock for holders
  • Filing: MyMD Pharmaceuticals (NASDAQ:MYMD) filed a prospectus for the offer and resale of up to 473,841 shares of common stock by selling stockholders.
  • Filing: The prospectus is not an offer to sell but relates to the mentioned shares.
  • More on MyMD Pharmaceuticals: Additional information about MyMD Pharmaceuticals was provided in the news article.
  • Financial information for MyMD Pharmaceuticals: The article may contain financial details or updates related to MyMD Pharmaceuticals.
-.-
2024-05-21SeekingAlpha
Tandem Diabetes Care, Guardion Health, GT Biopharma among healthcare movers
Wall Street analysts forecast MYMD stock price to rise
0 Analyst Rating
Wall Street analysts forecast MYMD stock price to rise
0 Buy
0 Hold
0 Sell
Current: 0.000
sliders
Low
Averages
High
Current: 0.000
sliders
Low
Averages
High
No data

No data

Valuation Metrics

The current forward P/E ratio for Mymd Pharmaceuticals Inc (MYMD.O) is --, compared to its 5-year average forward P/E of --. For a more detailed relative valuation and DCF analysis to assess Mymd Pharmaceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
Current PE
NaN
Overvalued PE
Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
Current EV/EBITDA
NaN
Overvalued EV/EBITDA
Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
Current PS
NaN
Overvalued PS
Undervalued PS

Financials

AI Analysis
Annual
Quarterly

Whales Holding MYMD

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Mymd Pharmaceuticals Inc (MYMD) stock price today?

The current price of MYMD is 0 USD — it has increased 0

What is Mymd Pharmaceuticals Inc (MYMD)'s business?

MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).

What is the price predicton of MYMD Stock?

Wall Street analysts forecast MYMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYMD is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Mymd Pharmaceuticals Inc (MYMD)'s revenue for the last quarter?

Mymd Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is Mymd Pharmaceuticals Inc (MYMD)'s earnings per share (EPS) for the last quarter?

Mymd Pharmaceuticals Inc. EPS for the last quarter amounts to 0.06 USD, decreased -166.67

How many employees does Mymd Pharmaceuticals Inc (MYMD). have?

Mymd Pharmaceuticals Inc (MYMD) has 9 emplpoyees as of March 12 2026.

What is Mymd Pharmaceuticals Inc (MYMD) market cap?

Today MYMD has the market capitalization of 4.34M USD.